Checkpoint Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity - Additional Information (Details)

Stockholders' Equity - Additional Information (Details)		1 Months Ended	3 Months Ended		6 Months Ended
Stockholders' Equity - Additional Information (Details)	Jan. 01, 2022 shares	Jan. 31, 2022 shares	Jun. 30, 2022 USD ($) Vote $ / shares shares	Jun. 30, 2021 USD ($) shares	Jun. 30, 2022 USD ($) Vote $ / shares shares	Jun. 30, 2021 USD ($) shares	Dec. 31, 2021 $ / shares shares	Jun. 09, 2021 $ / shares shares	Nov. 30, 2020 USD ($)	Jun. 30, 2020 shares	Mar. 17, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares authorized \| shares			135,000,000		135,000,000		135,000,000	135,000,000
Common Stock, Increase in authorized shares (in shares) \| shares								40,000,000
Common stock, par or stated value per share \| $ / shares			$ 0.0001		$ 0.0001		$ 0.0001	$ 0.0001
Common stock, shares outstanding \| shares			84,905,751		84,905,751		77,574,405
Shelf registration statement, maximum authorized securities \| $									$ 100,000,000
Percentage of annual equity fee											2.50%
Issuance of common shares, net of offering costs - At-the-market offering \| $			$ 642,000	$ 10,824,000	$ 8,687,000	$ 34,717,000
Issuance of common shares - Founders Agreement \| $			17,000	$ 253,000	213,000	$ 887,000
Shelf registration statement remaining authorized securities \| $			45,700,000		45,700,000
Non-vested Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation cost related to non-vested \| $			$ 4,200,000		$ 4,200,000
Weighted average period (in years)					2 years 1 month 6 days
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock outstanding non-vested \| shares			513,334		513,334
2015 Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for issuance Authorized \| shares										9,000,000
Plans expires (in years)					10 years
Shares are available for issuance \| shares			2,188,471		2,188,471
At the Market Offering
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares sold \| shares					4,305,644
Sale price per share \| $ / shares			$ 2.07		$ 2.07
Aggregate total gross proceeds from shares sold \| $					$ 8,900,000
Net proceeds from the offering \| $					$ 8,700,000
Stock issued during period shares common shares for at the market offering \| shares					4,305,644
Stock issued during period value common shares for at the market offering gross \| $					$ 8,900,000
Issuance of common shares, net of offering costs - At-the-market offering \| $					8,700,000
Commissions and other transaction costs \| $					$ 200,000
Fortress Biotech, Inc
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares sold \| shares	2,121,422	2,121,422			107,632
Percentage of annual equity fee	2.50%		2.50%		2.50%
Issuance of common shares - Founders Agreement \| $					$ 213,000
Agent
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Commission rate			3.00%		3.00%
Common Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period shares common shares for at the market offering \| shares			563,705	3,374,674	4,305,644	10,399,983
Issuance of common shares, net of offering costs - At-the-market offering \| $				$ 1,000		$ 2,000
Common Class A
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares authorized \| shares								7,000,000
Common stock, shares outstanding \| shares			7,000,000		7,000,000		7,000,000
Number of votes per share \| Vote			1		1